WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H326687
CAS#: 367514-88-3 (HCl)
Description: Lurasidone HCl, also known as SM-13496, is an atypical antipsychotic drug. In the USA since 2013, it is also approved for the treatment of depressive episodes associated with bipolar I disorder as well as bipolar II disorder in adults when used alone or in combination with lithium, valproate, or lamotrigine. Lurasidone may be useful for treating the cognitive and memory deficits seen in schizophrenia. Lurasidone has activity at several serotonin receptors that are involved in learning and memory.
Hodoodo Cat#: H326687
Name: Lurasidone HCl
CAS#: 367514-88-3 (HCl)
Chemical Formula: C28H37ClN4O2S
Exact Mass: 0.00
Molecular Weight: 529.140
Elemental Analysis: C, 63.56; H, 7.05; Cl, 6.70; N, 10.59; O, 6.05; S, 6.06
Related CAS #: 367514-88-3 (HCl) 367514-87-2 (Free base)
Synonym: SM-13496; SM 13496; SM13496; Lurasidone HCl. trade name Latuda.
IUPAC/Chemical Name: (3aR,4S,7R,7aS)-2-(((1R,2R)-2-((4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)methyl)cyclohexyl)methyl)hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione hydrochloride
InChi Key: NEKCRUIRPWNMLK-SCIYSFAVSA-N
InChi Code: InChI=1S/C28H36N4O2S.ClH/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26;/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2;1H/t18-,19+,20-,21-,24+,25-;/m0./s1
SMILES Code: O=C1N(C[C@H]2[C@H](CN3CCN(C4=NSC5=C4C=CC=C5)CC3)CCCC2)C([C@]6([H])[C@@](C7)([H])CC[C@@]7([H])[C@]16[H])=O.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: Related CAS# 367514-88-3 ( Lurasidone HCl); 367514-87-2 ( Lurasidone Free base).
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 529.14 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Awad G, Ng-Mak D, Rajagopalan K, Hsu J, Pikalov A, Loebel A. Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia. BMC Psychiatry. 2016 Jun 1;16:176. doi: 10.1186/s12888-016-0879-5. PubMed PMID: 27245981; PubMed Central PMCID: PMC4888300.
2: Lurasidone. Australas Psychiatry. 2016 Jun;24(3):313. doi: 10.1177/1039856216647220. PubMed PMID: 27231317.
3: Rajagopalan K, Bacci ED, Ng-Mak D, Wyrwich K, Pikalov A, Loebel A. Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials. BMC Psychiatry. 2016 May 23;16:157. doi: 10.1186/s12888-016-0865-y. PubMed PMID: 27215976; PubMed Central PMCID: PMC4877991.
4: Jaeschke RR, Sowa-Kućma M, Pańczyszyn-Trzewik P, Misztak P, Styczeń K, Datka W. Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile. Pharmacol Rep. 2016 Apr 22;68(4):748-755. doi: 10.1016/j.pharep.2016.04.002. [Epub ahead of print] Review. PubMed PMID: 27203278.
5: Krystal AD, Zammit G. The sleep effects of lurasidone: a placebo-controlled cross-over study using a 4-h phase-advance model of transient insomnia. Hum Psychopharmacol. 2016 May;31(3):206-16. doi: 10.1002/hup.2533. Epub 2016 Apr 25. PubMed PMID: 27108672.
6: Suppes T, Kroger H, Pikalov A, Loebel A. Lurasidone adjunctive with lithium or valproate for bipolar depression: A placebo-controlled trial utilizing prospective and retrospective enrolment cohorts. J Psychiatr Res. 2016 Jul;78:86-93. doi: 10.1016/j.jpsychires.2016.03.012. Epub 2016 Mar 31. PubMed PMID: 27089521.
7: Rajagopalan K, Trueman D, Crowe L, Squirrell D, Loebel A. Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia. Pharmacoeconomics. 2016 Jul;34(7):709-21. doi: 10.1007/s40273-016-0405-0. PubMed PMID: 27067724.
8: Correll CU, Cucchiaro J, Silva R, Hsu J, Pikalov A, Loebel A. Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study. CNS Spectr. 2016 Apr 6:1-10. [Epub ahead of print] PubMed PMID: 27048911.
9: Lurasidone. Aust Prescr. 2016 Feb;39(1):25-6. doi: 10.18773/austprescr.2016.001. Epub 2015 Nov 6. Review. PubMed PMID: 27041804; PubMed Central PMCID: PMC4816874.
10: Keks NA, Hope J, Castle D. Lurasidone: an antipsychotic with antidepressant effects in bipolar depression? Australas Psychiatry. 2016 Jun;24(3):289-91. doi: 10.1177/1039856216641309. Epub 2016 Apr 1. PubMed PMID: 27036122.
11: Ghori AK, Sajatovic M, Tampi RR. A Case of Emergent Restless Legs Syndrome With Lurasidone Therapy. J Clin Psychopharmacol. 2016 Jun;36(3):293-4. doi: 10.1097/JCP.0000000000000496. PubMed PMID: 27035496.
12: Kantrowitz JT, Sharif Z, Medalia A, Keefe RS, Harvey P, Bruder G, Barch DM, Choo T, Lee S, Lieberman JA. A multicenter, rater-blinded, randomized controlled study of auditory processing-focused cognitive remediation combined with open-label lurasidone in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2016 Mar 15. [Epub ahead of print] PubMed PMID: 27035157.
13: Rajagopalan K, Bacci ED, Wyrwich KW, Pikalov A, Loebel A. The direct and indirect effects of lurasidone monotherapy on functional improvement among patients with bipolar depression: results from a randomized placebo-controlled trial. Int J Bipolar Disord. 2016 Dec;4(1):7. doi: 10.1186/s40345-016-0049-1. Epub 2016 Mar 16. PubMed PMID: 26928122; PubMed Central PMCID: PMC4792823.
14: Ketter TA, Sarma K, Silva R, Kroger H, Cucchiaro J, Loebel A. LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY. Depress Anxiety. 2016 May;33(5):424-34. doi: 10.1002/da.22479. Epub 2016 Feb 26. PubMed PMID: 26918425.
15: Potkin SG, Kimura T, Guarino J. A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia. Ther Adv Psychopharmacol. 2015 Dec;5(6):322-31. doi: 10.1177/2045125315606027. Erratum in: Ther Adv Psychopharmacol. 2015 Dec;5(6):369. PubMed PMID: 26834965; PubMed Central PMCID: PMC4722503.
16: Loebel A, Xu J, Hsu J, Cucchiaro J, Pikalov A. The development of lurasidone for bipolar depression. Ann N Y Acad Sci. 2015 Nov;1358:95-104. doi: 10.1111/nyas.12965. Review. PubMed PMID: 26771990.
17: Loebel A, Citrome L. Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression. BJPsych Bull. 2015 Oct;39(5):237-41. doi: 10.1192/pb.bp.114.048793. PubMed PMID: 26755968; PubMed Central PMCID: PMC4706192.
18: Calabrese F, Savino E, Papp M, Molteni R, Riva MA. Chronic mild stress-induced alterations of clock gene expression in rat prefrontal cortex: modulatory effects of prolonged lurasidone treatment. Pharmacol Res. 2016 Feb;104:140-50. doi: 10.1016/j.phrs.2015.12.023. Epub 2015 Dec 29. PubMed PMID: 26742719.
19: Chapel S, Chiu YY, Hsu J, Cucchiaro J, Loebel A. Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis. Clin Ther. 2016 Jan 1;38(1):4-15. doi: 10.1016/j.clinthera.2015.11.013. Epub 2015 Dec 22. PubMed PMID: 26730454.
20: Calabrese J, Rajagopalan K, Ng-Mak D, Bacci ED, Wyrwich K, Pikalov A, Loebel A. Effect of lurasidone on meaningful change in health-related quality of life in patients with bipolar depression. Int Clin Psychopharmacol. 2016 May;31(3):147-54. doi: 10.1097/YIC.0000000000000116. PubMed PMID: 26717493.
